| 1E8Y |
2.0 |
Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine |
| 1E8Z |
2.4 |
Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin and staurosporine |
| 1HE8 |
3.0 |
Ras G12V - PI 3-kinase gamma complex |
| 2A4Z |
2.9 |
Crystal Structure of human PI3Kgamma complexed with AS604850 |
| 2A5U |
2.7 |
Crystal Structure of human PI3Kgamma complexed with AS605240 |
| 2CHW |
2.6 |
A pharmacological map of the PI3-K family defines a role for p110 alpha in signaling: The structure of complex of phosphoinositide 3- kinase gamma with inhibitor PIK-39 |
| 2CHX |
2.5 |
A pharmacological map of the PI3-K family defines a role for p110alpha in signaling: The structure of complex of phosphoinositide 3-kinase gamma with inhibitor PIK-90 |
| 2CHZ |
2.6 |
A pharmacological map of the PI3-K family defines a role for p110alpha in signaling: The structure of complex of phosphoinositide 3-kinase gamma with inhibitor PIK-93 |
| 2V4L |
2.5 |
complex of human phosphoinositide 3-kinase catalytic subunit gamma (p110 gamma) with PIK-284 |
| 3APC |
2.544 |
Crystal structure of human PI3K-gamma in complex with CH5132799 |
| 3APD |
2.55 |
Crystal structure of human PI3K-gamma in complex with CH5108134 |
| 3APF |
2.82 |
Crystal structure of human PI3K-gamma in complex with CH5039699 |
| 3CSF |
2.8 |
Crystal structure of PI3K p110gamma catalytical domain in complex with organoruthenium inhibitor DW2 |
| 3CST |
3.2 |
Crystal structure of PI3K p110gamma catalytical domain in complex with organoruthenium inhibitor E5E2 |
| 3DBS |
2.8 |
Structure of PI3K gamma in complex with GDC0941 |
| 3DPD |
2.85 |
Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-Dihydro-2H-benzo[1,4]oxazines |
| 3ENE |
2.4 |
Complex of PI3K gamma with an inhibitor |
| 3IBE |
2.798 |
Crystal Structure of a Pyrazolopyrimidine Inhibitor Bound to PI3 Kinase Gamma |
| 3L08 |
2.7 |
Structure of Pi3K gamma with a potent inhibitor: GSK2126458 |
| 3L13 |
3.0 |
Crystal Structures of Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors |
| 3L16 |
2.9 |
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer |
| 3L17 |
3.0 |
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer |
| 3L54 |
2.3 |
Structure of Pi3K gamma with inhibitor |
| 3LJ3 |
2.43 |
PI3-kinase-gamma with a pyrrolopyridine-benzofuran inhibitor |
| 3MJW |
2.87 |
PI3 Kinase gamma with a benzofuranone inhibitor |
| 3ML8 |
2.7 |
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04691502 through Structure Based Drug Design |
| 3ML9 |
2.55 |
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04691502 through Structure Based Drug Design |
| 3NZS |
2.75 |
Structure-based Optimization of Pyrazolo -Pyrimidine and -Pyridine Inhibitors of PI3-Kinase |
| 3NZU |
2.6 |
Structure-based Optimization of Pyrazolo -Pyrimidine and -Pyridine Inhibitors of PI3-Kinase |
| 3OAW |
2.75 |
4-Methylpteridineones as Orally Active and Selective PI3K/mTOR Dual Inhibitors |
| 3P2B |
3.2 |
Crystal Structure of PI3K gamma with 3-(2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenol |
| 3PRE |
2.91 |
Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors. |
| 3PRZ |
2.6 |
Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors. |
| 3PS6 |
2.6 |
Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors. |
| 3QAQ |
2.9 |
Crystal structure of PI3K-gamma in complex with triazine-benzimidazole 1 |
| 3QAR |
2.65 |
Crystal structure of PI3K-gamma in complex with triazine-benzimidazole 32 |
| 3QJZ |
2.9 |
Crystal structure of PI3K-gamma in complex with benzothiazole 1 |
| 3QK0 |
2.85 |
Crystal structure of PI3K-gamma in complex with benzothiazole 82 |
| 3R7Q |
2.5 |
Structure-based design of thienobenzoxepin inhibitors of PI3- kinase |
| 3R7R |
2.9 |
Structure-based design of thienobenzoxepin inhibitors of PI3-Kinase |
| 3S2A |
2.55 |
Crystal structure of PI3K-gamma in complex with a quinoline inhibitor |
| 3SD5 |
3.2 |
Crystal Structure of PI3K gamma with 5-(2,4-dimorpholinopyrimidin-6-yl)-4-(trifluoromethyl)pyridin-2-amine |
| 3T8M |
2.5 |
Rational Design of PI3K-alpha Inhibitors that Exhibit Selectivity Over the PI3K-beta Isoform |
| 3TJP |
2.7 |
Crystal Structure of PI3K gamma with N6-(3,4-dimethoxyphenyl)-2-morpholino-[4,5'-bipyrimidine]-2',6-diamine |
| 3TL5 |
2.788 |
Discovery of GDC-0980: a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor for the Treatment of Cancer |
| 3ZVV |
2.5 |
Fragment Bound to PI3Kinase gamma |
| 3ZW3 |
2.8 |
Fragment based discovery of a novel and selective PI3 Kinase inhibitor |
| 4ANU |
2.81 |
Complexes of PI3Kgamma with isoform selective inhibitors. |
| 4ANV |
2.13 |
Complexes of PI3Kgamma with isoform selective inhibitors. |
| 4ANW |
2.31 |
Complexes of PI3Kgamma with isoform selective inhibitors. |
| 4ANX |
2.73 |
Complexes of PI3Kgamma with isoform selective inhibitors. |
| 4AOF |
3.3 |
Selective small molecule inhibitor discovered by chemoproteomic assay platform reveals regulation of Th17 cell differentiation by PI3Kgamma |
| 4DK5 |
2.95 |
Crystal structure of human PI3K-gamma in complex with a pyridyl-triazine inhibitor |
| 4EZJ |
2.67 |
Potent and Selective Inhibitors of PI3K-delta: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf |
| 4EZK |
2.803 |
Potent and Selective Inhibitors of PI3K-delta: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf |
| 4EZL |
2.94 |
Potent and Selective Inhibitors of PI3K-delta: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf |
| 4F1S |
3.0 |
Crystal structure of human PI3K-gamma in complex with a pyridyl-triazine-sulfonamide inhibitor |
| 4FA6 |
2.7 |
Design and Synthesis of a Novel Pyrrolidinyl Pyrido Pyrimidinone Derivative as a Potent Inhibitor of PI3Ka and mTOR |
| 4FAD |
2.7 |
Design and Synthesis of a Novel Pyrrolidinyl Pyrido Pyrimidinone Derivative as a Potent Inhibitor of PI3Ka and mTOR |
| 4FHJ |
2.6 |
Crystal Structure of PI3K-gamma in Complex with Imidazopyridine 2 |
| 4FHK |
3.0 |
Crystal Structure of PI3K-gamma in Complex with Imidazopyridazine 19e |
| 4FJY |
2.9 |
Crystal structure of PI3K-gamma in complex with quinoline-indoline inhibitor 24f |
| 4FJZ |
3.0 |
Crystal structure of PI3K-gamma in complex with pyrrolo-pyridine inhibitor 63 |
| 4FLH |
2.6 |
Crystal structure of human PI3K-gamma in complex with AMG511 |
| 4FUL |
2.47 |
PI3 Kinase Gamma bound to a pyrmidine inhibitor |
| 4G11 |
3.4 |
X-ray structure of PI3K-gamma bound to a 4-(morpholin-4-yl)- (6-oxo-1,6-dihydropyrimidin-2-yl)amide inhibitor |
| 4GB9 |
2.438 |
Potent and Highly Selective Benzimidazole Inhibitors of PI3K-delta |
| 4HLE |
2.78 |
Compound 21 (1-alkyl-substituted 1,2,4-triazoles) |
| 4HVB |
2.35 |
Catalytic unit of PI3Kg in complex with PI3K/mTOR dual inhibitor PF-04979064 |
| 4J6I |
2.9 |
Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase beta isoform |
| 4KZ0 |
2.87 |
Structure of PI3K gamma with Imidazopyridine inhibitors |
| 4KZC |
3.25 |
Structure of PI3K gamma with Imidazopyridine inhibitors |
| 4PS3 |
2.9 |
Structure of PI3K gamma in complex with 1-[6-(5-methoxypyridin-3-yl)-1,3-benzothiazol-2-yl]-3-[2-(1-propyl-1H-imidazol-4-yl)ethyl]urea |
| 4PS7 |
2.69 |
Structure of PI3K gamma in complex with N-[6-(pyridin-3-yl)-1,3-benzothiazol-2-yl]acetamide |
| 4PS8 |
2.99 |
Structure of PI3K gamma in complex with N-[6-(5,6-dimethoxypyridin-3-yl)-1,3-benzothiazol-2-yl]acetamide |
| 4URK |
2.9 |
PI3Kg in complex with AZD6482 |
| 4WWN |
2.7 |
Crystal structure of human PI3K-gamma in complex with (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine AMG319 inhibitor |
| 4WWO |
2.3 |
Crystal structure of human PI3K-gamma in complex with phenylquinoline inhibitor N-{(1S)-1-[8-chloro-2-(3-fluorophenyl)quinolin-3-yl]ethyl}-9H-purin-6-amine |
| 4WWP |
2.4 |
Crystal structure of human PI3K-gamma in complex with pyridinylquinoline inhibitor N-{(1S)-1-[8-chloro-2-(2-methylpyridin-3-yl)quinolin-3-yl]ethyl}-9H-purin-6-amine |
| 4XX5 |
2.76 |
Structure of PI3K gamma in complex with an inhibitor |
| 4XZ4 |
2.6 |
Structure of PI3K gamma in complex with an inhibitor |
| 5EDS |
2.8 |
Crystal structure of human PI3K-gamma in complex with benzimidazole inhibitor 5 |
| 5G2N |
2.68 |
X-ray structure of PI3Kinase Gamma in complex with Copanlisib |
| 5G55 |
2.45 |
3-Quinoline Carboxamides inhibitors of Pi3K |
| 5JHA |
2.51 |
Structure of Phosphoinositide 3-kinase gamma (PI3K) bound to the potent inhibitor PIKin2 |
| 5JHB |
2.48 |
Structure of Phosphoinositide 3-kinase gamma (PI3K) bound to the potent inhibitor PIKin3 |
| 5KAE |
2.65 |
Crystal structure of human PI3K-gamma in complex with quinoline-containing inhibitor 5g |
| 5OQ4 |
2.7 |
PQR309 - a Potent, Brain-Penetrant, Orally Bioavailable, pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology |
| 5T23 |
2.78 |
PI3Kg IN COMPLEX WITH 5d |
| 6AUD |
2.015 |
PI3K-gamma K802T in complex with Cpd 8 10-((1-(tert-butyl)piperidin-4-yl)sulfinyl)-2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine |
| 6C1S |
2.31 |
Phosphoinositide 3-Kinase gamma bound to an pyrrolopyridinone Inhibitor |
| 6FH5 |
2.84 |
PI3Kg IN COMPLEX WITH Compound 7 |
| 6GQ7 |
2.84 |
PI3Kg IN COMPLEX WITH INH |
| 6T3B |
3.01 |
Crystal structure of PI3Kgamma with a dihydropurinone inhibitor (compound 4) |
| 6T3C |
2.62 |
Crystal structure of PI3Kgamma in complex with DNA-PK inhibitor AZD7648 |
| 6XRL |
2.99 |
Crystal structure of human PI3K-gamma in complex with inhibitor IPI-549 |
| 6XRM |
2.88 |
Crystal structure of human PI3K-gamma in complex with Compound 4 |
| 6XRN |
2.96 |
Crystal structure of human PI3K-gamma in complex with Compound 17 |
| 7JWE |
2.55 |
Gedatolisib bound to the PI3Kg catalytic subunit p110 gamma |
| 7JWZ |
2.65 |
IPI-549 bound to the PI3Kg catalytic subunit p110 gamma |
| 7JX0 |
3.15 |
NVS-PI3-4 bound to the PI3Kg catalytic subunit p110 gamma |
| 7KKE |
2.81 |
Phosphoinositide 3-Kinase gamma bound to a thiazole inhibitor |
| 7MEZ |
2.89 |
Structure of the phosphoinositide 3-kinase p110 gamma (PIK3CG) p101 (PIK3R5) complex |
| 7Z61 |
2.738 |
Crystal structure of PI3Kgamma with a dihydropurinone inhibitor (compound 18) |
